Ghrelin vs Myostatin Propeptide

Must be acylated at Ser3 (by GOAT enzyme) for GHSR-1a binding. Receptor activation in the pituitary stimulates GH release; hypothalamic action via NPY/AgRP neurons increases appetite and reduces energy expenditure.

Ghrelin is an endogenous 28-amino-acid peptide hormone produced primarily by X/A-like cells of the gastric fundus, characterized by a unique octanoyl modification at Ser3 required for GHS-R1a receptor binding; it is the endogenous ligand for the growth hormone secretagogue receptor and functions as a dual regulator of GH secretion and energy homeostasis. Ghrelin acts centrally via hypothalamic GHS-R1a receptors to potently stimulate GH release from the pituitary and to promote appetite through NPY/AgRP pathway activation, and has peripheral effects on gastric motility and insulin secretion, establishing it as a key integrator of nutritional status, GH axis activity, and energy balance. The pharmacology of GHS-R1a activation in humans is validated through macimorelin (Macrilen), an FDA-approved oral ghrelin receptor agonist; Phase 1 and Phase 2 randomized controlled trials of macimorelin demonstrated robust and reliable GH stimulation in adults, supporting FDA approval in 2017 for the diagnosis of adult GH deficiency and confirming the human physiological relevance of ghrelin receptor activation. Ghrelin itself is not therapeutically administered; it has a very short plasma half-life and the active acylated form is rapidly degraded in circulation; FDA-approved ghrelin receptor agonists require prescription and are indicated for diagnostic rather than therapeutic use, while ghrelin peptide is used exclusively as a research tool compound in neuroendocrine pharmacology studies.

Endogenous N-terminal fragment of myostatin precursor; binds and neutralizes mature myostatin (GDF-8); naturally produced to regulate the extent of muscle inhibition

Myostatin propeptide is the endogenous N-terminal prodomain of the precursor myostatin protein (GDF-8) that, following cleavage of the mature myostatin dimer, remains non-covalently associated with it as a latency-associated complex, maintaining the active growth factor in an inactive state until proteolytic activation by BMP-1/tolloid family metalloproteinases releases it to engage ActRIIB receptors and signal through the Smad2/3 pathway. Recombinant versions of the propeptide can act as endogenous-mechanism inhibitors of myostatin by sequestering the mature peptide in an inactive complex, reducing the inhibitory signaling that myostatin exerts on skeletal muscle protein synthesis and satellite cell activity in the ActRII/Smad pathway. Foundational rodent studies demonstrate that overexpression of the myostatin propeptide produces significant skeletal muscle hypertrophy, and the BMP-1/tolloid proteolytic activation mechanism of the propeptide-myostatin latent complex has been characterized genetically in mouse models. Myostatin propeptide is a research compound with no regulatory approval in any jurisdiction; recombinant propeptide administration has not been evaluated in human clinical trials for muscle building or performance applications, and no human safety or pharmacokinetic data has been established.